Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New National Cancer Standards For Sarcoma Services Published, Wales
New standards to improve access to diagnosis and treatment of sarcomas have been published by the Welsh Assembly Government.

Dr. David B. Samadi Introduces New Prostate Cancer Care Center For Robotic Surgery Patients At Mount Sinai Medical Center
The Mount Sinai Medical Center has a new re center for prostate cancer treatment. Led by David B. Samadi, M.D., Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology, the new state-of-the-art facility at 625 Madison Avenue in New York City specializes in pre- and post-surgery care for patients who undergo a robotic prostatectomy at Mount Sinai"s main campus. It also provides expertise in the treatment of other urologic cancers, including bladder and kidney. A multilingual staff offers assistance with patient travel arrangements, accommodations, and translation services when required.
News of the day
House Democrats Hope To Forge Deal On Package, Wait For Score
As they worked to move health care reform legislation through the Energy and Commerce Committee, House Democrats said they were close to a compromise with fiscally conservative Democrats, a group that so far has been a roadblock, The Hill reports.
Medical Devices

UCB's CIMZIA(R) (certolizumab Pegol) Approved By The U.S. FDA For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis

UCB announced that the U.S. Food and Drug Administration (FDA) approved Cimzia®, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four weeks can be considered. In clinical trials with Cimzia®, together with methotrexate (MTX), patients experienced a significant reduction in the signs and symptoms of RA at week 24 with some showing clinical responses within one to two weeks, compared with MTX alone. Additionally, radiographic data showed Cimzia®, together with MTX, inhibited progression of joint damage, with a significantly smaller change from baseline in modified Total Sharp Score (TSS) at 24 and 52 weeks of treatment, compared with MTX alone (p CIMZIA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009